Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1948 1
1950 2
1951 1
1952 2
1953 3
1954 3
1956 1
1957 1
1958 1
1961 4
1962 3
1963 21
1964 19
1965 28
1966 19
1967 19
1968 49
1969 42
1970 38
1971 33
1972 23
1973 31
1974 25
1975 33
1976 36
1977 48
1978 50
1979 52
1980 67
1981 79
1982 89
1983 94
1984 108
1985 91
1986 101
1987 97
1988 125
1989 162
1990 126
1991 148
1992 178
1993 183
1994 184
1995 213
1996 203
1997 212
1998 234
1999 275
2000 284
2001 285
2002 307
2003 332
2004 329
2005 383
2006 381
2007 436
2008 390
2009 410
2010 444
2011 467
2012 539
2013 590
2014 549
2015 595
2016 589
2017 660
2018 668
2019 678
2020 789
2021 814
2022 818
2023 772
2024 750
2025 112

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,315 results

Results by year

Filters applied: . Clear all
Page 1
Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Löhr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators. Stone JH, et al. Among authors: tanaka y. N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Online ahead of print. N Engl J Med. 2024. PMID: 39541094
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Nash P, et al. Among authors: tanaka y. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.
Durvalumab-induced Severe Gastritis.
Otohara M, Kawamoto K, Tanaka Y, Taniwaki M. Otohara M, et al. Among authors: tanaka y. Intern Med. 2022 Jul 15;61(14):2239-2240. doi: 10.2169/internalmedicine.8292-21. Epub 2021 Dec 28. Intern Med. 2022. PMID: 34980792 Free PMC article. No abstract available.
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Cohen SB, et al. Among authors: tanaka y. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. RMD Open. 2020. PMID: 33127856 Free PMC article. Clinical Trial.
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.
Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, Chak E, Coffin CS, Fujiwara K, Gankina N, Gordon SC, Janczewska E, Komori A, Lampertico P, McPherson S, Morozov V, Plesniak R, Poulin S, Ryan P, Sagalova O, Sheng G, Voloshina N, Xie Q, Yim HJ, Dixon S, Paff M, Felton L, Lee M, Greene T, Lim J, Lakshminarayanan D, McGonagle G, Plein H, Youssef AS, Elston R, Kendrick S, Theodore D. Buti M, et al. Among authors: tanaka y. J Hepatol. 2025 Feb;82(2):222-234. doi: 10.1016/j.jhep.2024.08.010. Epub 2024 Aug 29. J Hepatol. 2025. PMID: 39214467 Free article. Clinical Trial.
Gateway Reflex and Mechanotransduction.
Matsuyama S, Tanaka Y, Hasebe R, Hojyo S, Murakami M. Matsuyama S, et al. Among authors: tanaka y. Front Immunol. 2021 Dec 22;12:780451. doi: 10.3389/fimmu.2021.780451. eCollection 2021. Front Immunol. 2021. PMID: 35003096 Free PMC article. Review.
Pulmonary osteoclast-like cells in silica induced pulmonary fibrosis.
Hasegawa Y, Franks JM, Tanaka Y, Uehara Y, Read DF, Williams C, Srivatsan S, Pitstick LB, Nikolaidis NM, Shaver CM, Kropski J, Ware LB, Taylor CJ, Banovich NE, Wu H, Gardner JC, Osterburg AR, Yu JJ, Kopras EJ, Teitelbaum SL, Wikenheiser-Brokamp KA, Trapnell C, McCormack FX. Hasegawa Y, et al. Among authors: tanaka y. Sci Adv. 2024 Jul 12;10(28):eadl4913. doi: 10.1126/sciadv.adl4913. Epub 2024 Jul 10. Sci Adv. 2024. PMID: 38985878 Free PMC article.
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies.
Lu Z, Verginadis I, Kumazoe M, Castillo GM, Yao Y, Guerra RE, Bicher S, You M, McClung G, Qiu R, Xiao Z, Miao Z, George SS, Beiting DP, Nojiri T, Tanaka Y, Fujimura Y, Onda H, Hatakeyama Y, Nishimoto-Ashfield A, Bykova K, Guo W, Fan Y, Buynov NM, Diehl JA, Stanger BZ, Tachibana H, Gade TP, Puré E, Koumenis C, Bolotin EM, Fuchs SY. Lu Z, et al. Among authors: tanaka y. Sci Transl Med. 2024 Aug 21;16(761):eadn0904. doi: 10.1126/scitranslmed.adn0904. Epub 2024 Aug 21. Sci Transl Med. 2024. PMID: 39167664
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RBM, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC. Mease PJ, et al. Among authors: tanaka y. Rheumatol Ther. 2024 Oct;11(5):1363-1382. doi: 10.1007/s40744-024-00708-8. Epub 2024 Aug 31. Rheumatol Ther. 2024. PMID: 39215949 Free PMC article.
15,315 results
You have reached the last available page of results. Please see the User Guide for more information.